BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pyxis Oncology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Pyxis Oncology's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06795412-10913@assetmemo.bio
DTSTAMP:20261121T010438Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Micvotabart pelidotin: Phase 1/2 readout est. (NCT06795412)
DESCRIPTION:Micvotabart pelidotin\, phase 1/2\, Solid Tumors.\nStudy: Phase
  1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid 
 Tumors\nEstimated primary completion: 6 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/micvotabart-pelidotin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06795412
URL:https://assetmemo.bio/drug/micvotabart-pelidotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
